Authors
Latest:
Giants of Cancer Care® Announces the 11th Annual Class of InducteesOncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum sponsor) and Exelixis and Stemline (gold sponsors), are pleased to announce the inductees of the 11th Annual Giants of Cancer Care recognition program.
Latest:
Dr. Liauw on RT Advancements in Prostate CancerStanley Liauw, MD, associate professor at the University of Chicago Medicine, discusses the advancements in radiation therapy (RT) over the last several years, and how he has seen the treatment affect his patients.
Latest:
Dr. Stanley Yap on Sequential Therapy for Muscle-Invasive Bladder CancerStanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses sequential therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Latest:
Medicaid Expansion Plans Provide Novel Approaches for Healthcare CoverageThe US Supreme Court's decision to uphold the Affordable Care Act but allow states to decide whether to expand Medicaid has raised a question in many states: Where political leaders have been opposed or split on President Obama's healthcare reforms, is it smart or foolish to cover more people?
Latest:
Dr. Aebi on Adjuvant Chemo in Recurrent Breast CancerStefan Aebi, MD, from the Luzerner Kantonsspital, Switzerland, discusses findings from the CALOR trial that examined the administration of adjuvant chemotherapy for women recurrent breast cancer.
Latest:
Dr. Faderl on Chemotherapy and FLT3 Inhibitors in AMLStefan Faderl, MD, chief, Leukemia Division, John Theurer Cancer Center, discusses combining and sequencing chemotherapy and FLT3 inhibitors for the treatment of patients with acute myeloid leukemia (AML).
Latest:
Stefani Spranger on the Role of CD8 T Cells in MelanomaStefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago Medicine, discusses how the presence or absence of CD8 T cells can affect treatment approaches for patients with melanoma.
Latest:
Developing Treatment for Invasive Lobular CarcinomaSteffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC).
Latest:
Dr. Grupp on the Optimal Setting of CAR T-Cell Therapy in ALLStephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
Mining the Pipeline: Leading Investigational Products and Areas of Unmet NeedThe oncology pipeline is crowded, despite the fact that the agents in development target a broad range of tumor types.
Latest:
Extending the Promise of Immunotherapy to Pancreatic CancerStephanie K. Dougan, PhD, assistant professor, microbiology and immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways to extend the promise of immunotherapy to the field of pancreatic cancer.
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast CancerDrs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.
Latest:
Acquisitions by 340B Hospitals Drive Up Healthcare CostsAs the 340B drug discount program has ballooned in size over the last several years, some hospitals are getting creative about how to make the program work for their own financial gain.
Latest:
Dr. Boorjian on Research With Nadofaragene Firadenovec in Nonmuscle Invasive Bladder CancerStephen A. Boorjian, MD, professor of urology, Mayo Clinic, discusses research with intravesical nadofaragene firadenovec in patients with nonmuscle invasive bladder cancer (NMIBC).
Latest:
Dr. Ansell on the Updated Analysis of ECHELON-1 in Classical Hodgkin LymphomaStephen M. Ansell, MD, PhD, discusses the updated analysis of the phase 3 ECHELON-1 in classical Hodgkin lymphoma.
Latest:
Dr. Malamud on Key Data From KATHERINE Study in HER2+ Breast CancerStephen C. Malamud, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses key data from the KATHERINE study in the treatment of patients with HER2-positive breast cancer.
Latest:
Dr. Nimer on CAR T-Cell Therapy in Hematologic MalignanciesStephen D. Nimer, MD, professor of medicine, director, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.
Latest:
Dr. Emerson Explains the Connection Between Stem Cell Mutations and LeukemiaStephen G Emerson, MD, PhD, Clyde Wu Professor of Immunology and Medicine, director, Herbert Irving Comprehensive Cancer Center, explains the connection between stem cell mutations and leukemia.
Latest:
Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALLStephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).
Latest:
Dr. Stephen Huang on Challenges in Pediatric Thyroid CancerStephen Huang, MD, Associate Professor of Pediatrics, Harvard Medical School, Dana Farber Cancer Institute, discusses the challenges of pediatric thyroid cancer.
Latest:
Final Thoughts on CSPCExperts offer concluding remarks on castration-sensitive prostate cancer, sharing their perspectives on the evolving field and expressing their aspirations for future advancements in disease treatment.
Latest:
Dr. Johnston on the Results of monarchE With Abemaciclib in High-Risk Early Breast CancerStephen Johnston, MA, PhD, FRCP, discusses the results of the phase 3 monarchE study examining the addition of abemaciclib to endocrine therapy in patients with high-risk early hormone receptor–positive, HER2-negative breast cancer.
